Added to YB: 2026-01-08
Pitch date: 2026-01-06
GRCE [neutral]
Grace Therapeutics, Inc.
+2.19%
current return
Author Info
No bio for this author
Company Info
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Market Cap
$56.2M
Pitch Price
$3.65
Price Target
11.10 (+206%)
Dividend
N/A
EV/EBITDA
-3.15
P/E
-6.64
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Grace Therapeutics 2026 Updated Primer: 4 Months Until PDUFA
GRCE (update - long): First IV nimodipine for aSAH hits Ph3 primary endpoint (19% reduction in hypotension vs oral). 100% bioavailability vs 7% oral, solving 40yr old dosing problems. Orphan designation, 7yr exclusivity. 90% PoS for April 2026 PDUFA. 40k patient TAM, $500/day pricing like Nymalize. Peak sales $125M, 45% penetration. Trading 0.5x risk-adj peak sales vs 2.3x fair value. Base PT $11.10 (3x upside).
Read full article (28 min)